Invivyd (NASDAQ:IVVD) Earns Buy Rating from HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Invivyd in a research report on Thursday, March 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Invivyd currently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Stock Performance

Shares of NASDAQ:IVVD opened at $0.61 on Wednesday. Invivyd has a 52-week low of $0.35 and a 52-week high of $4.74. The business’s 50 day simple moving average is $1.00 and its two-hundred day simple moving average is $0.86. The firm has a market cap of $73.18 million, a P/E ratio of -0.31 and a beta of 0.09.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10. The firm had revenue of $13.80 million during the quarter, compared to the consensus estimate of $13.57 million. On average, equities analysts forecast that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Terrance Mcguire sold 86,545 shares of Invivyd stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the completion of the transaction, the director now directly owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. The trade was a 2.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 17.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Invivyd

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its position in shares of Invivyd by 290.5% in the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after purchasing an additional 87,358 shares in the last quarter. Barclays PLC boosted its stake in Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock worth $56,000 after purchasing an additional 9,207 shares during the period. Renaissance Technologies LLC purchased a new position in Invivyd during the 4th quarter valued at about $74,000. JPMorgan Chase & Co. increased its position in shares of Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after buying an additional 222,375 shares during the period. Finally, Two Sigma Advisers LP increased its position in shares of Invivyd by 1,276.5% during the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after buying an additional 282,100 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.